Non-Hodgkin Lymphoma MSK-16-873 (CHRONOS 4)

The purpose of this study is to compare treatment with copanlisib plus standard immunochemotherapy (This combines two powerful treatments: immunotherapy and chemotherapy) with immunochemotherapy alone in patients with slow-growing non-Hodgkin lymphoma (NHL) that has come back despite prior treatment. Standard immunochemotherapy includes the drug rituximab with either bendamustine or CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone).

Copanlisib is a newer anticancer drug. It is designed to slow down cancer growth by blocking the activity of an enzyme cancer cells need called PI3 kinase. There will be a safety “lead-in” phase where all patients will receive copanlisib with immunochemotherapy). After that, patients will be randomly assigned (by chance) to receive standard immunochemotherapy with copanlisib or with a placebo. All of the medications used in this study are given by vein.

Eligibility

Patients must have indolent (slow-growing) CD20-positive NHL that has come back despite prior treatment that included rituximab. Patients must also be able to walk and do routine activities for more than half of their normal waking hours.

This study is for patients age 18 and older.

Available at: Hartford Hospital